bgb-16673
Small moleculeexperimental
Clinical trial activity
9 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
4
Phase 3
3
Phase 4
0
Earliest trial started Nov 15, 2021 (NCT05006716)
Timeline
Indications
Studied for
- Chronic Urticaria · Phase 1
- Healthy Volunteers · Phase 1
- Leukemia, B-Cell · Phase 1/Phase 2
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 3
- Lymphoma, B-Cell · Phase 1/Phase 2
- Lymphoma, B-Cell, Marginal Zone · Phase 1
- Lymphoma, Follicular · Phase 1
- Lymphoma, Large B-Cell, Diffuse · Phase 1
- Lymphoma, Large-Cell, Immunoblastic · Phase 1
- Lymphoma, Mantle-Cell · Phase 1
- Lymphoma, Non-Hodgkin · Phase 1
- Neoplasms · Phase 1/Phase 2
- Waldenstrom Macroglobulinemia · Phase 1
Mechanism of action
- Tyrosine-protein kinase BTKDEGRADER
BTK degrader
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06973187 | Phase 3 | Sep 4, 2025 | BeOne Medicines |
| NCT07005713 | Phase 1 | Jul 19, 2025 | BeOne Medicines |
| NCT06970743 | Phase 3 | May 29, 2025 | BeOne Medicines |
| NCT06846671 | Phase 3 | Apr 11, 2025 | BeOne Medicines |
| NCT06906809 | Phase 1 | Apr 3, 2025 | BeOne Medicines |
| NCT06776679 | Phase 1 | Jan 24, 2025 | BeOne Medicines |
| NCT06634589 | Phase 1/Phase 2 (Phase 2) | Dec 2, 2024 | BeOne Medicines |
| NCT05294731 | Phase 1 | Mar 24, 2022 | BeOne Medicines |
| NCT05006716 | Phase 1 | Nov 15, 2021 | BeOne Medicines |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| BeOne Medicines | For profit | 9 | 9 | 3 | 2021 |
1 organizations
Page 1 / 1